Cinvanti, Emend (aprepitant) is a small molecule pharmaceutical. Aprepitant was first approved as Cinvanti on 2003-03-26. It has been approved in Europe to treat neoplasms, postoperative nausea and vomiting, and vomiting. The pharmaceutical is active against substance-P receptor. Emend's patents are valid until 2035-09-18 (FDA).
|Indication||neoplasms, postoperative nausea and vomiting, vomiting|
|Drug Class||Tachykinin (neurokinin) receptor antagonists: NK1 receptor antagonists|